Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.32 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | KLK7 | P49862 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21292940 | 1.00 | PLA2G2C (0.38) | PLA2G2CCA2MAPK1TAS1R3TAS1R1 | |
| SCHEMBL1388452 | 0.74 | CA2 (0.48) | PLA2G2CCA2MAPK1TAS1R3TAS1R1 | |
| SCHEMBL4856257 | 0.74 | PLA2G2C (0.56) | PLA2G2CCA2MAPK1PLA2G10 | |
| SCHEMBL20914941 | 0.74 | PLA2G2C (0.51) | PLA2G2CCA2MAPK1TAS1R3TAS1R1 | |
| SCHEMBL4820679 | 0.72 | PLA2G2C (0.46) | PLA2G2CCA2MAPK1PLA2G10CNR2 | |
| SCHEMBL4820666 | 0.72 | PLA2G2C (0.46) | PLA2G2CCA2MAPK1PLA2G10CNR2 | |
| SCHEMBL16762206 | 0.72 | PLA2G2C (0.46) | PLA2G2CCA2MAPK1PLA2G10CNR2 | |
| SCHEMBL5953705 | 0.72 | PLA2G2C (0.59) | PLA2G2CCA2PLA2G10 | |
| SCHEMBL4856599 | 0.72 | PLA2G2C (0.59) | PLA2G2CCA2PLA2G10 | |
| Hydrochloric Acid SCHEMBL10822847 | 0.72 | CA2 (0.47) | PLA2G2CCA2MAPK1TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | MOLECULAR SKIN THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | PLA2G2C 1914/4885CA2 1576/4885MAPK1 3912/4885 |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | AIFM2, GPX4, GPX1 | PLA2G2C 2301/4885CA2 1719/4885MAPK1 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.